Insurance Coverage News: Only 1 in 5 Large Companies Cover Wegovy for Weight Loss

Current Insurance Landscape for Weight-Loss Medications

When it comes to insurance coverage for weight-loss drugs like Wegovy and Zepbound, recent research indicates that only 1 in 5 large U.S. companies offer these treatments under their health plans. The Health Affairs report highlights the escalating costs associated with these GLP-1 medications, which can exceed $1,000 a month and impede access for many employees. Employers are confronted with the challenge of balancing health benefits against rising prescription drug spending.

Impact on Employee Health and Access

About 40% of U.S. adults struggle with obesity, a condition that contributes to various health issues. The restrictions on coverage amplify existing health disparities, particularly among low- and middle-income individuals. Employers face mounting pressure to find a viable solution amid growing concerns about the high costs of these necessary treatments.

Employer Insights

• Approximately half of employers do not cover GLP-1 weight-loss drugs.
• Nearly a third are unsure about their coverage status.
• Only 3% of firms not covering these drugs are likely to add them in the next year.

Many employers implementing coverage are also placing additional requirements on their health plans, such as dietitian consultations, which may restrict employee access further. Strong future interest in covering these medications indicates a potential change in policy, but overcoming economic constraints remains a significant hurdle.